To inhibit Akt, two commercially available inhibitors, Akt inhibitor IV and VIII (Calbiochem), and a clinically available Akt inhibitor, Miltefosine, approved for treatment of breast cancer were used. This evidence concerns the gene AKT1 and breast cancer.